Synopsis: The shares of this pharmaceutical company could deliver 20 percent PAT growth and achieve a 24 percent EBITDA margin, backed by strong chronic therapy growth and management guidance.
The article outlines a pharma stock with robust guidance, which is a pharmaceutical company developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management, urology, and other therapeutic areas
With a market capitalization of Rs 12,709 crore, Corona Remedies Ltd’s share closed at Rs 2,078 per share, up by 0.65 percent from the previous close. The stock trades at an overvalued P/E of 64x compared to the industry P/E of 35x, as it has a PEG ratio of 1.92x. Management Guidance
PE investors continue to hold stake
Private equity investors, including Sepia, continue to hold around 14 percent of the company. Management said there are no indications that these investors are looking to reduce their stake further, easing concerns about additional selling pressure.
Q4 margin pressure expected to ease
The company’s Q4 FY26 margins were impacted by the expansion of its medical representative (MR) workforce. Management expects this pressure to ease in the coming quarters as the larger sales team starts contributing to higher revenue and better operating leverage.
FY27 guidance
The company has guided for 15 percent organic revenue growth and 20 percent PAT growth in FY27. Management also targets an EBITDA margin of 24 percent over the next four to five years, driven by steady business expansion and improved profitability.
Wokadine growth outlook
Management clarified that the FY27 revenue guidance excludes contributions from Bayer and the Wokadine portfolio. On a steady-state basis, it expects around 15 percent revenue growth and 20 percent net profit growth organically, while the Wokadine portfolio is expected to grow at around 25 percent annually over the next three years.
How does the company make its revenue?
The company has changed its revenue mix over the last decade by focusing more on chronic medicines, which are taken for long-term diseases and provide steady, recurring demand. The share of chronic therapies increased from 45.3 percent in FY16 to 71.9 percent in FY26, while acute therapies declined from 54.7 percent to 28.1 percent. This strategy has helped the company grow faster than the Indian Pharmaceutical Market (IPM).
The company has also shifted its focus towards high-growth therapy areas. The contribution from the “Others” category fell from 63.7 percent in FY16 to 32.8 percent in FY26, while Women’s Healthcare increased from 23.7 percent to 27.5 percent and Cardio Diabeto grew sharply from 6.2 percent to 25.4 percent. The share of Pain Management also increased from 6.3 percent to 11.4 percent, while Urology rose from 2.0 percent to 2.9 percent, helping the company build a stronger portfolio.
The company has also diversified its geographical presence to reduce dependence on a single region. Revenue contribution from the West declined from 66.2 percent in FY16 to 45.2 percent in FY26, while the South, North, and East increased their share to 20.8 percent, 20.0 percent, and 14.0 percent, respectively. A wider presence across India has helped the company strengthen its market reach and create a more balanced business.
About the Company
Corona Remedies Limited is a prominent, fast-growing Indian pharmaceutical company headquartered in Ahmedabad, Gujarat. Founded in 2004, it has advanced into the top 40 pharmaceutical organizations in India, specializing in developing, manufacturing, and marketing high-quality, prescription-based medicines.
Financial Highlights: Revenue from operations of Rs 353 crore, compared to Rs 294 crore in Q4 FY25, registering a growth of around 20 percent YoY. Operating profit margin remained steady at around 18 percent in Q4 FY26, unchanged from 18 percent in Q4 FY25. Net profit rose to Rs 45 crore in Q4 FY26 from Rs 31 crore in Q4 FY25, up around 45 percent YoY, while EPS increased to Rs 7.37 in Q4 FY26 from Rs 5.12 in Q4 FY25, reflecting a growth of about 44 percent.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
